Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017144636) HIGH BIOAVAILABILITY OROMUCOSAL PHARMACEUTICAL PREPARATIONS BASED ON CYCLODEXTRIN AND SUCRALOSE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/144636 International Application No.: PCT/EP2017/054274
Publication Date: 31.08.2017 International Filing Date: 24.02.2017
Chapter 2 Demand Filed: 14.09.2017
IPC:
A61K 47/69 (2017.01) ,A61P 13/10 (2006.01)
[IPC code unknown for A61K 47/69]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13
Drugs for disorders of the urinary system
10
of the bladder
Applicants:
ALTERGON S.A. [CH/CH]; Via Dogana Vecchia, 2 6901 Lugano, CH
Inventors:
BELLORINI, Lorenzo; IT
NOCELLI, Luca; IT
FOSSATI, Tiziano; IT
Agent:
GERLI, Paolo; IT
Priority Data:
10201600001903024.02.2016IT
Title (EN) HIGH BIOAVAILABILITY OROMUCOSAL PHARMACEUTICAL PREPARATIONS BASED ON CYCLODEXTRIN AND SUCRALOSE
(FR) PRÉPARATIONS PHARMACEUTIQUES OROMUQUEUSES À BIODISPONIBILITÉ ÉLEVÉE À BASE DE CYCLODEXTRINE ET DE SUCRALOSE
Abstract:
(EN) The invention relates to a new composite based on hydroxypropyl-β-cyclodextrin, sucralose, a pharmaceutically active ingredient (API) complexed in said hydroxypropyl-β-cyclodextrin, and optionally an aqueous vehicle. The composite is obtainable by a complexation process of the API in hydroxypropyl-β-cyclodextrin, carried out in the presence of sucralose. The composite ensures a surprisingly high API bioavailability through buccal route of absorption, due to a high absorption rate through the oral membrane. The composite is therefore suitable for the preparation of oromucosal pharmaceutical compositions, e.g. buccal or sublingual tablets, orodispersible film, etc., having high bioavailability.
(FR) La présente invention concerne un nouveau composite à base d'hydroxypropyl-β-cyclodextrine, de sucralose, d’un composant pharmaceutiquement actif (API) complexé dans ladite hydroxypropyl-β-cyclodextrine, et facultativement un véhicule aqueux. Le composite peut être obtenu par un processus de complexation de l'API dans l'hydroxypropyl-β-cyclodextrine, en présence de sucralose. Le composite assure une biodisponibilité d’API étonnamment élevée par voie d'absorption buccale, grâce à un taux d'absorption élevé à travers la membrane buccale. Par conséquent, le composite est adapté pour la préparation de compositions pharmaceutiques oromuqueuses, par exemple des comprimés buccaux ou sublinguaux, un film orodispersible, etc., ayant une biodisponibilité élevée.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)